121 related articles for article (PubMed ID: 25593988)
1. Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.
Aggoune D; Tosca L; Sorel N; Bonnet ML; Dkhissi F; Tachdjian G; Bennaceur-Griscelli A; Chomel JC; Turhan AG
Oncoscience; 2014; 1(1):57-68. PubMed ID: 25593988
[TBL] [Abstract][Full Text] [Related]
2. The molecular signature of
Baassiri A; Ghais A; Kurdi A; Rahal E; Nasr R; Shirinian M
iScience; 2024 Apr; 27(4):109538. PubMed ID: 38585663
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib-review of historical development, current status, and future research.
Kantarjian HM; Chifotides HT; Haddad FG; Short NJ; Loghavi S; Jabbour E
Am J Hematol; 2024 May; ():. PubMed ID: 38727135
[TBL] [Abstract][Full Text] [Related]
4. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.
Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F
Am J Physiol Cell Physiol; 2024 Jun; ():. PubMed ID: 38826137
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.
Nicolini FE; Huguet F; Huynh L; Xu C; Bouvier C; Yocolly A; Etienne G
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627189
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Analysis of
Majumdar A; Katara R; Mishra A; Gupta A; Sharma DK; Srivastava AK; Sharma S; Jaiswal A; Dixit M; Kumar V; Kumar S; Kumar V; Sharma R; Mohanty SK
South Asian J Cancer; 2024 Apr; 13(2):132-141. PubMed ID: 38919665
[TBL] [Abstract][Full Text] [Related]
7. High
Massimino M; Stella S; Tirrò E; Pennisi MS; Stagno F; Vitale SR; Romano C; Tomarchio C; Parrinello NL; Manzella L; Di Raimondo F; Vigneri P
Onco Targets Ther; 2023; 16():803-816. PubMed ID: 37807980
[TBL] [Abstract][Full Text] [Related]
8. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE; Sasaki K; Kim DW; Hughes TP; Etienne G; Mauro MJ; Hochhaus A; Lang F; Heinrich MC; Breccia M; Deininger M; Goh YT; Janssen JJWM; Talpaz M; de Soria VGG; le Coutre P; DeAngelo DJ; Damon A; Cacciatore S; Polydoros F; Agrawal N; Rea D
Leukemia; 2024 May; ():. PubMed ID: 38755421
[TBL] [Abstract][Full Text] [Related]
9. Derivates of 1,6-dihyadroazaazulenes as inhibitors of tyrosine kinases BCR-ABL1 wild type and mutant T315I: a molecular dynamics approach.
Solís-Hernández MJ; Palomares-Báez JP; Herrera-Bucio R; Chacón-García L; Navarro-Santos P
J Biomol Struct Dyn; 2023 Nov; ():1-12. PubMed ID: 37937766
[TBL] [Abstract][Full Text] [Related]
10. Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds.
Larocque E; Chu EFY; Naganna N; Sintim HO
ACS Omega; 2020 Feb; 5(6):2690-2698. PubMed ID: 32095692
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL1 kinase: hunting an elusive target with new weapons.
Skorski T
Chem Biol; 2011 Nov; 18(11):1352-3. PubMed ID: 22118668
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Amino Acid Substitutions in ABL1 Protein Leading to Tumor Drug Resistance Based on "Structure-Property" Relationship Classification Models.
Zhuravleva SI; Zadorozhny AD; Shilov BV; Lagunin AA
Life (Basel); 2023 Aug; 13(9):. PubMed ID: 37763211
[TBL] [Abstract][Full Text] [Related]
13. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.
Ursan ID; Jiang R; Pickard EM; Lee TA; Ng D; Pickard AS
J Manag Care Spec Pharm; 2015 Feb; 21(2):114-22. PubMed ID: 25615000
[TBL] [Abstract][Full Text] [Related]
14. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.
Al-Achkar W; Moassass F; Ikhtiar A; Liehr T; Othman MA; Wafa A
Mol Cytogenet; 2014; 7(1):89. PubMed ID: 25621010
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Cerny-Reiterer S; Rabenhorst A; Stefanzl G; Herndlhofer S; Hoermann G; Müllauer L; Baumgartner S; Beham-Schmid C; Sperr WR; Mannhalter C; Sill H; Linkesch W; Arock M; Hartmann K; Valent P
Oncotarget; 2015 Feb; 6(5):3071-84. PubMed ID: 25605011
[TBL] [Abstract][Full Text] [Related]
16. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
18. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.
Mauro MJ; Davis C; Zyczynski T; Khoury HJ
Ther Adv Hematol; 2015 Feb; 6(1):3-14. PubMed ID: 25642311
[TBL] [Abstract][Full Text] [Related]
19. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
Vaidya S; Vundinti BR; Shanmukhaiah C; Chakrabarti P; Ghosh K
PLoS One; 2015; 10(1):e0114828. PubMed ID: 25629972
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Bourgne C; Janel A; Berger J; Rapatel C; Tournilhac O; Hermet E; Guerci A; Lioret F; Briançon A; Bamdad M; Boiret-Dupré N; Berger MG
Leuk Res; 2015 Mar; 39(3):329-34. PubMed ID: 25612940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
